Projects per year
Personal profile
Fingerprint
Dive into the research topics where Gabriel Rinnerthaler is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Most recent collaborations and top research areas
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Active
-
Tumor biological and immunological characterization of localized therapy-refractory triple-negative breast carcinomas
Rinnerthaler, G. (Principal investigator)
1/04/25 → 31/03/27
Project: Research funding
-
Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2-early breast cancer
Bartsch, R., Dormann, C., Egle, D., Gampenrieder, S., Pristauz-Telsnigg, G., Rinnerthaler, G., Singer, C. & Gnant, M., 2026, In: Wiener Klinische Wochenschrift. 13 p.Research output: Contribution to journal › Review
1 Citation (Web of Science) -
Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samples
Gassner, F., Rinnerthaler, G., Castagnaviz, V., Gonzalez-Martinez, A., Parigger, T., Drothler, S., Greil, R., Geisberger, R., Kraus, T., Romagna, A., Schwartz, C., Ladisich, B., Sotlar, K., Hauser-Kronberger, C., Alinger-Scharinger, B., Steiner, M., Zaborsky, N. & Gampenrieder, S., 29 Mar 2026, In: Scientific Reports. 16, 1, 9 p., 10721.Research output: Contribution to journal › Research article
-
Different types of electrostimulation target specific impaired sensory and motor functions in chemotherapy-induced peripheral neuropathy: a secondary analysis of a controlled trial
Rieder, F., Sassmann, R., Kienberger, Y., Castagnaviz, V., Schaffler-Schaden, D., Johansson, T., Rinnerthaler, G., Flamm, M., Greil, R., Schulze, C. & Gampenrieder, S., 2026, In: Frontiers in Neurology. 17, p. 1653161 7 p., 1653161.Research output: Contribution to journal › Research article
-
Efficacy of sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, in metastatic triple-negative breast cancer
Berton, F. (First author) & Rinnerthaler, G., 2026, In: Memo - Magazine of European Medical Oncology. 19, 5 p.Research output: Contribution to journal › Review
-
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria
Dobric, N. (First author), Hasenleithner, S., Suppan, C., Klocker, E. V., Hlauschek, D., Graf, R., Beichler, C., Albertini, C., Egle, D., Liu, D., Starzer, A., Bartsch, R., Moser, T., Rinnerthaler, G., Jost, P., Heitzer, E., Dandachi, N. & Balic, M., Apr 2026, In: ESMO Open. 11, 4, p. 106939 12 p., 106939.Research output: Contribution to journal › Research article
Activities
- 3 Poster
-
Extended adjuvant (adj) neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine - interim analysis of the multinational, prospective, non-interventional study (NIS) ELEANOR (n=300)
Breitenstein, U. (Author), Wrobel, D. (Author), Guth, D. (Author), Zaiss, M. (Author), Terhaag, J. (Author), Zahn, M. (Author), Perlova-Griff, L. (Author), Distelrath, A. (Author), Wuerstlein, R. (Author), Apel, K. (Author), Deuerling, N. (Author), Vannier, C. (Author), Bartsch, R. (Author), Jackisch, C. (Author), Mueller, V. (Author), Schmidt, M. (Author), Balic, M. (Author), Rinnerthaler, G. (Author), Lueftner, D. (Author), Zaman, K. (Author), Schwitter, M. (Author) & Harbeck, N. (Author)
2025Activity: Talk, presentation or poster › Poster
-
Circulating tumor DNA profiling of patients with metastatic luminal HER2-low and HER2-0 breast cancer via next-generation sequencing.
Dobri, N. (Author), Dandachi, N. (Author), Klocker, E. V. (Author), Suppan, C. (Author), Graf, R. (Author), Lazzeri, I. (Author), Albertini, C. (Author), Rinnerthaler, G. (Author), Starzer, A. (Author), Bartsch, R. (Author), Hasenleithner, S. (Author), Jost, P. (Author), Heitzer, E. (Author) & Balic, M. (Author)
2025Activity: Talk, presentation or poster › Poster
-
Predictive role of baseline [18F]FDG PET/CT quantitative parameters for response to neoadjuvant treatment with atezolizumab, trastuzumab, pertuzumab and epirubicin in HER2-positive early breast cancer - a substudy of the ABCSG-52/ATHENE phase II trial
Beheshti, M. (Author), Rinnerthaler, G. (Author), Farbod, A. (Author), Hitzl, W. (Author), Egle, D. (Author), Gampenrieder, S. (Author), Bartsch, R. (Author), Balic, M. (Author), Greil, R. (Author), Gnant, M. (Author) & Pirich, C. (Author)
2024Activity: Talk, presentation or poster › Poster
Prizes
-
"Claus" Award, 2. Platz
Hoffmann, M. (Recipient), Sendlhofer, G. (Recipient), Loder, C. (Recipient), Rinnerthaler, G. (Recipient) & Bauernhofer, T. (Recipient), 2026
Prize